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In the previous issue of Arthritis Research & Th  erapy, 
Pineda and colleagues present an interesting study evalu-
at  ing the use of ultrasonography (US) to help identify 
hyperuricemic individuals at risk for gouty arthritis [1]. 
Hyperuricemia is the most important risk factor for 
gouty arthritis. Th   e number of adults with hyperuricemia 
and gouty arthritis is increasing.
Th   e National Health and Nutrition Examination Survey 
(NHANES) data from 2007 to 2008 showed a hyper-
uricemia (serum urate ≥7 mg/dl) prevalence of 21.1% in 
men and 4.7% in women [2]. Most individuals with 
hyperuricemia, however, do not develop gouty arthritis 
[3]. Th   e reported gouty arthritis prevalence in the 2007 to 
2008 NHANES data was 5.9% in men and 2% in women, 
with an overall prevalence of 3.9% (8.3 million adults) [4]. 
Th   e risk of developing gouty arthritis is dependent on the 
severity of hyperuricemia. In the Normative Aging Study, 
healthy patients with serum urate levels ≥9 mg/dl upon 
entry into the study had a cumulative incidence of acute 
ﬂ  ares that reached 22% after 5 years, whereas those with 
serum urate levels ≤7 mg/dl had an annual incidence of 
only 0.5% [5]. In yet another study, the 5-year prevalence 
of gouty arthritis was 30% in individuals with serum urate 
levels >10 g/dl [6]. Th  ese numbers correlate with the 
recently reported NHANES data.
Th  e quandary is how to predict which patient with 
asymptomatic hyperuricemia will develop gouty arthritis, 
and thus who will beneﬁ  t from-long term anti-inﬂ  am-
matory and urate-lowering therapy. Serum urate levels 
and gouty arthritis prevalence are related to genetic 
variations in the SLC2A9, ABCG2 and SLC17A3 genes. 
Dehghan and colleagues developed a risk score based on 
variations of these three genetic loci. Th   ey suggested that 
their genetic risk score is associated with up to a 40-fold 
increased risk of developing gouty arthritis, suggesting 
that knowledge of the genotype may help identify 
hyperuricemic individuals at risk for developing gouty 
arthritis [7]. Can US serve as another potential method to 
help identify hyperuricemic individuals at risk for 
developing gouty arthritis?
Over the past several years, there has been a growing 
interest in musculoskeletal US in rheumatology. US visual-
izes tissues as acoustic reﬂ  ections. Crystalline material 
reﬂ  ects US waves more strongly than the surround  ing 
tissues, such as unmineralized hyaline cartilage or 
synovial ﬂ  uid. Th  is enables distinction of monosodium 
urate (MSU) crystal deposition from the less echogenic 
surrounding soft tissues. MSU crystals are found in 
cartilage, tendon sheaths, synovial ﬂ   uid and sub  cuta-
neous tissue. US detects deposition of MSU crystals on 
cartilaginous surfaces, as well as tophaceous material and 
typical erosions. A hyperechoic, irregular band over the 
superﬁ  cial margin of the articular cartilage – described 
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© 2011 BioMed Central Ltdas a double contour sign or icing – is found exclusively in 
gouty arthritis [8] and represents crystalline precipitates 
of MSU. In addition, the presence of hypoechoic to 
hyper  echoic inhomogeneous material surrounded by a 
small anechoic rim, representing tophaceous material 
and erosions adjacent to tophaceous material on US, are 
suggestive of the diagnosis of gouty arthritis. US is 
superior in detecting changes of gouty arthritis compared 
with other imaging modalities (magnetic resonance 
imag  ing, plain X-ray scans, computed tomography and 
three-dimensional rendering imaging) [9].
Pineda and colleagues support previous evidence that 
US may be useful in detecting gouty arthritis in hyper-
uricemic patients [1]. Puig and colleagues reported that 
34% (n = 12) of their asymptomatic hyperuricemic indi-
viduals had ﬁ  ndings suggestive of tophaceous deposits 
[10]. Pineda and colleagues also studied a larger cohort in 
a controlled fashion [1]. US images of the most 
commonly aﬀ  ected joints – knees, ankles and ﬁ  rst meta-
tarsophalangeals – were obtained. Th  e double contour 
sign and tophi were seen ultrasono  graphically in the knee 
hyaline cartilage and the ﬁ  rst  metatarsophalangeals. 
Tendinous inﬁ  ltrations of tophaceous material were also 
observed. Interestingly, tendinous tophi and entheso-
pathies were not a rare ﬁ   nding in these patients. US 
changes suggestive of gouty arthritis were found in 25% 
of hyperuricemic individuals. Th   ese changes were found 
exclusively in the hyperuricemic individuals but not in 
their control group of normouricemic individuals. Th  e 
main limitation of both Puig and colleagues’ study [10] 
and Pineda and colleagues’ study [1] is that the US 
ﬁ   ndings suggestive of gouty arthritis, tophi and the 
double contour sign were not proven MSU crystals. In 
both studies, therefore, a deﬁ   nite diagnosis of gouty 
arthritis was not established.
Whether ﬁ   nding sonographic evidence suggestive of 
gouty arthritis prior to development of acute ﬂ  ares will 
inﬂ  uence our decision of when to initiate and commit to 
a long-term urate-lowering therapy and chronic anti-
inﬂ  ammatory treatment is still to be determined. US may 
serve as a noninvasive means to diagnose gouty arthritis 
in hyperuricemic individuals who have yet to develop 
symptomatic gouty arthritis. How long hyperuricemia 
must be present before MSU crystal deposition can be 
seen sonographically is currently not known. Future 
large, prospective, randomized controlled trials of 
patients with proven MSU crystal gouty arthritis are 
needed to further evaluate the use of US to predict the 
presence of asymptomatic gouty arthritis in an individual 
hyperuricemic patient.
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